AI Cancer Detection Startup C the Signs Secures $8M to Revolutionise Early Diagnosis

C the Signs, a pioneering company in AI-powered cancer detection, has secured $8 million in funding from Khosla Ventures. This significant investment marks a crucial step in the company's journey to expand its innovative technology from the United Kingdom to the United StatesFounded with the mission to revolutionise early cancer detection, C the Signs has developed an AI-based platform that identifies patients at risk of cancer at the earliest and most curable stages. The company's approach fills a critical gap between cancer screening and diagnostic tests, offering a more precise and cost-effective solution

Dr. Bea Bakshi, Co-Founder and CEO of C the Signs, emphasized the importance of their mission: "We started C the Signs to move the burden of identifying cancer risk away from the emergency room, when it's often too late. Instead, we want to enable primary care physicians to identify cancer risk at the earliest possible stage, to substantially increase the chance of survival". The company's AI model analyzes data from patient electronic health records, going beyond basic risk indicators like age and gender. It examines a wide range of personal and environmental data points to accurately assess an individual's cancer risk. This personalised approach allows the platform to flag high-risk individuals who need targeted testing while ruling out those who do not.

C the Signs has already demonstrated impressive results within the UK's National Health Service (NHS). The platform has identified 20.7% of breast cancer cases up to five years earlier than standard pathways and improved early-stage diagnosis of ovarian cancer by 53.3% compared to traditional methods.Recent data presented at the 2025 ASCO Gastrointestinal Cancers Symposium showcased the platform's effectiveness in detecting colorectal cancer. Using its AI model on the records of 894,275 patients registered in the Mayo Data Platform, C the Signs achieved a sensitivity of 93.8% and a specificity of 19.7% in identifying patients at risk of colorectal cancer

Hal Paz of Khosla Ventures expressed enthusiasm for the investment: "Early cancer detection is the best way to beat the disease, and AI is primed to catch warning signs long before symptoms appear. By leveraging patient clinical and medical data, C the Signs helps physicians personalise care, predict health risks, improve care coordination, and enhance early intervention efforts" The funding from Khosla Ventures will accelerate C the Signs' expansion into the U.S. market, where the company aims to replicate its success in early cancer detection. This move could potentially transform cancer care in the United States by enabling primary care physicians to identify cancer risks at the earliest possible stage.C the Signs is backed by a group of notable investors, including MMC, Ataraxia, and Acequia Capital, alongside angel investors such as the past CEO of AXA Health, past CEO of Bupa, and the Founder of Monzo.As C the Signs prepares to enter the U.S. market, the company's AI-powered approach to early cancer detection holds the promise of significantly improving cancer survival rates. By detecting tumors when they can still be treated at stage 1 or 2, C the Signs increases survival odds compared to later-stage diagnoses.The investment from Khosla Ventures not only provides financial support but also validates the potential of C the Signs' technology to revolutionize cancer care.

As the company expands its reach, it moves closer to its goal of giving every patient the best possible chance of surviving cancer.